AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant hypertension, boos...

Evusheld is the first long-acting antibody to receive emergency use authorisation in the US for pre-exposure prophylaxis of COVID-19, in ad...

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for m...

The drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said ...

The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...

The agency said there were "no or limited data to change current recommendations." It said it wasn't known whether the risk of a rare blood...

The decision was announced soon after the European Union's drug regulator said it had found a ``possible link'' between the AstraZeneca cor...

The has been communication of scientific results. November data from trials in the U.K. and Brazil generated confusion over efficacy. This ...

The U.S. study comprised 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got dummy shots. The results were announed...

As a key facet of this association, the company has unveiled a three-year patient awareness programme, 'Beyond Sugar', developed to benefit...

The decision to put the trials on hold was taken by the members of the DSMB after they were informed about the serious adverse events repor...

Last month, the Drug Controller General of India had granted permission to the Pune-based SII to conduct Phase-II and -III human clinical t...

The drug known as AZD7442 has the potential to be given as a preventative option for people exposed to the coronavirus, and to treat and pr...

Blood-thinning drug Brilinta by AstraZeneca is safe to use in ambulance but giving it early in provides no extra benefit.

Britain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.

Cognizant has inked a deal with AstraZeneca to deliver comprehensive biostatistics and medical reporting services for generating clinical s...